Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice

Journal of Infectious Diseases

Volumn 190, Issue 6, 2004, Pages 1132-1139

  Smee, Donald F ^a   Bailey, Kevin W ^a   Wong, Min Hui ^a   Wandersee, Miles K ^a   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; BRAIN; CYCLOPHOSPHAMIDE; CYTOSINE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIVER; LUNG; MICE; MICE, INBRED HRS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PLAQUE ASSAY; SKIN; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; SURVIVAL ANALYSIS; TIME FACTORS; VACCINIA;

EID: 3543142885     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422696     Document Type: Article

References (25)

1. Fenner F. Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci 1993; 15:397-420.
2. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part I: background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003; 37:241-50.
3. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 2003; 58:101-14.
4. Breman IG, Henderson DS. Poxvirus dilemmas - monkeypox, smallpox and biological terrorism. N Engl J Med 1998; 339:556-9.
5. Peters CJ. Many viruses are potential agents of bioterrorism. ASM News 2002; 68:168-73.
6. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000; 181:10-9.
7. Smee DF, Bailey KW, Sidwell RW. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 2001; 12:71-6.
8. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46:991-5.
9. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hosteller KY, Kern ER. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48:404-12.
10. Neyts J, De Clercq E. Efficacy of 2-amino-7-(1,3-dihydroxy-2- propoxymethyl)purine for the treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother 2001; 45:84-7.
11. Smee DF, Bailey KW, Sidwell RW. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl] purine and its orally active diacetate ester prodrug. Antiviral Res 2002; 54:113-20.
12. Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 2003; 57:41-52.
13. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993; 41:242-6.
14. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002; 46:1329-35.
15. Hanlon CA, Niezgoda M, Shankar V, Niu HS, Koprowski H, Rupprecht CE. A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics. Vaccine 1997; 15:140-8.
16. Smee DF, Burger RA, Coombs J, Huffman JH, Sidwell RW. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosphamide treatment. J Infect Dis 1991; 164:958-61.
17. Smee DF, Burger RA, Warren RP, Bailey KW, Sidwell RW. An immunosuppressed mouse model of lethal murine gammaherpesvirus 68 infection for studying potential treatment of Epstein-Barr virus infection in man. Antivir Chem Chemother 1997; 8:573-81.
18. Selgrade MK, Daniels MJ, Hu PC, Miller FJ, Graham JA. Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity. Infect Immun 1982; 38:1046-55.
19. Smee DF, Morris JLB, Leonhardt JA, Mead JR, Holy A, Sidwell RW. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother 1992; 36:1837-42.
20. Worthington M, Rabson AS, Baron S. Mechanism of recovery from systemic vaccinia virus infection. 1. The effects of cyclophosphamide. J Exp Med 1972; 136:277-90.
21. Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136:983-5.
22. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992; 41:197-202.
23. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002; 55:1-13.
24. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997; 25:911-4.
25. Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 1996; 29:153-61.